

# EXHIBIT G

CERTIFICATION OF NAMED PLAINTIFF  
PURSUANT TO FEDERAL SECURITIES LAWS

STRATHCLYDE PENSION FUND (“Plaintiff”) declares:

1. Plaintiff has reviewed a complaint and authorized its filing.
2. Plaintiff did not acquire the security that is the subject of this action at the direction of plaintiff’s counsel or in order to participate in this private action or any other litigation under the federal securities laws.
3. Plaintiff is willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
4. Plaintiff has made the following transaction(s) during the Class Period in the securities that are the subject of this action:

<u>Security</u>	<u>Transaction</u>	<u>Date</u>	<u>Price Per Share</u>
-----------------	--------------------	-------------	------------------------

*See attached Schedule A*

5. Plaintiff has not sought to serve or served as a representative party in a class action that was filed under the federal securities laws within the three-year period prior to the date of this Certification except as detailed below:

*In re Ply Gem Holdings, Inc. Sec. Litig.*, No. 1:14-cv-03577 (S.D.N.Y.)  
*Makhlouf v. Tailored Brands, Inc., et al.*, No. 4:16-cv-00838 (S.D. Tex.)  
*Melbourne Municipal Firefighters’ v. Express Scripts Holding Company*, No. 1:16-cv-03338 (S.D.N.Y.)

6. The Plaintiff will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff’s pro rata share of

ALLERGAN

any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.

I declare under penalty of perjury that the foregoing is true and correct.  
Executed this 21<sup>st</sup> day of December, 2016.

STRATHCLYDE PENSION FUND

By: \_\_\_\_\_

  
Richard Keery, Investment Manager

## SCHEDULE A

## SECURITIES TRANSACTIONS

## Acquisitions

<u>Date Acquired</u>	<u>Type/Amount of Securities Acquired</u>	<u>Price</u>
7/1/2014 <sup>A</sup>	9,688	\$224.00
3/17/2015 <sup>B</sup>	12,265	\$307.51
03/20/2015	2,400	\$317.06
08/24/2015	460	\$297.16
12/18/2015	600	\$307.28
02/10/2016	35,134	\$278.36
02/11/2016	22,740	\$273.99
02/12/2016	16,626	\$275.45
04/13/2016	14,748	\$221.08
04/13/2016	16,552	\$220.46
05/17/2016	545	\$227.58
05/20/2016	14,400	\$229.51
07/06/2016	420	\$236.61
07/13/2016	2,200	\$243.17
07/14/2016	430	\$243.60
07/14/2016	5,800	\$242.57
08/30/2016	5,100	\$237.30
10/13/2016	19,200	\$232.86
10/14/2016	13,600	\$232.74
10/18/2016	11,288	\$228.55
10/19/2016	8,712	\$229.22
10/31/2016	1,133	\$208.94

## Sales

<u>Date Sold</u>	<u>Type/Amount of Securities Sold</u>	<u>Price</u>
7/17/2014 <sup>C</sup>	1	\$213.66
3/31/2015 <sup>C</sup>	1	\$297.62

\*Opening position of 18,407 shares.

<sup>A</sup>Shares exchanged in Forest Laboratories merger. Valued at closing price on date of merger.

<sup>B</sup>Shares exchanged in Allergan Inc. merger. Valued at closing price on date of merger.

<sup>C</sup>Sale of fractions. Valued at closing price.